These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 22743980)

  • 1. Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars.
    Berkowitz SA; Engen JR; Mazzeo JR; Jones GB
    Nat Rev Drug Discov; 2012 Jun; 11(7):527-40. PubMed ID: 22743980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications.
    Duivelshof BL; Jiskoot W; Beck A; Veuthey JL; Guillarme D; D'Atri V
    Anal Chim Acta; 2019 Dec; 1089():1-18. PubMed ID: 31627805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioanalytical challenges of biosimilars.
    Islam R
    Bioanalysis; 2014 Feb; 6(3):349-56. PubMed ID: 24471955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosimilars: the need, the challenge, the future: the FDA perspective.
    Epstein MS; Ehrenpreis ED; Kulkarni PM;
    Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: what the oncologist should know.
    Thill M; Thatcher N; Hanes V; Lyman GH
    Future Oncol; 2019 Apr; 15(10):1147-1165. PubMed ID: 30793950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glycan characterization of biopharmaceuticals: Updates and perspectives.
    Planinc A; Bones J; Dejaegher B; Van Antwerpen P; Delporte C
    Anal Chim Acta; 2016 May; 921():13-27. PubMed ID: 27126786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing analytical comparability for "biosimilars": filgrastim as a case study.
    Rathore AS; Bhambure R
    Anal Bioanal Chem; 2014 Oct; 406(26):6569-76. PubMed ID: 24866713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilar therapeutics-what do we need to consider?
    Schellekens H
    NDT Plus; 2009 Jan; 2(Suppl_1):i27-i36. PubMed ID: 19461855
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Biosimilars in rheumatology and other fields of medicine].
    Milchert M; Fliciński J; Brzosko M
    Postepy Hig Med Dosw (Online); 2014 Jul; 68():970-5. PubMed ID: 25055035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.
    Buske C; Ogura M; Kwon HC; Yoon SW
    Future Oncol; 2017 May; 13(15s):5-16. PubMed ID: 28482702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Developing clinical trials for biosimilars.
    Bui LA; Taylor C
    Semin Oncol; 2014 Feb; 41 Suppl 1():S15-25. PubMed ID: 24560024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologics and biosimilars.
    Patel PK; King CR; Feldman SR
    J Dermatolog Treat; 2015; 26(4):299-302. PubMed ID: 26105205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing the Totality of Evidence for Biosimilars: Regulatory Considerations and Building Confidence for the Healthcare Community.
    Markus R; Liu J; Ramchandani M; Landa D; Born T; Kaur P
    BioDrugs; 2017 Jun; 31(3):175-187. PubMed ID: 28439817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biosimilars: Rationale and current regulatory landscape.
    Olech E
    Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biosimilars: current scientific and regulatory considerations.
    Chugh PK; Roy V
    Curr Clin Pharmacol; 2014 Feb; 9(1):53-63. PubMed ID: 23952143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biosimilars in oncology: from development to clinical practice.
    Rak Tkaczuk KH; Jacobs IA
    Semin Oncol; 2014 Apr; 41 Suppl 3():S3-S12. PubMed ID: 24767633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Polish Task Force position statement on safety of biologic treatment with monoclonal antibodies and soluble receptors].
    Jahnz-Rozyk K; Wiesik-Szewczyk E;
    Pol Merkur Lekarski; 2014 Jul; 37(217):5-9. PubMed ID: 25154192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars for the treatment of infectious diseases: the case of biosimilar interferons.
    El-Sherbeini M
    Drugs Today (Barc); 2011 Jun; 47(6):431-40. PubMed ID: 21695285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.